# Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

> **NCT04320888** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Hematopoietic and Lymphatic System Neoplasm
- Recurrent Ependymoma
- Recurrent Ewing Sarcoma
- Recurrent Hepatoblastoma
- Recurrent Histiocytic and Dendritic Cell Neoplasm
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Lymphoma
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Glioma
- Recurrent Malignant Solid Neoplasm
- Recurrent Medulloblastoma
- Recurrent Neuroblastoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Recurrent Peripheral Primitive Neuroectodermal Tumor
- Recurrent Rhabdoid Tumor
- Recurrent Rhabdomyosarcoma
- Recurrent Soft Tissue Sarcoma
- Recurrent WHO Grade 2 Glioma
- Refractory Ependymoma
- Refractory Ewing Sarcoma
- Refractory Hepatoblastoma
- Refractory Histiocytic and Dendritic Cell Neoplasm
- Refractory Langerhans Cell Histiocytosis
- Refractory Lymphoma
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Glioma
- Refractory Malignant Solid Neoplasm
- Refractory Medulloblastoma
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Osteosarcoma
- Refractory Peripheral Primitive Neuroectodermal Tumor
- Refractory Rhabdoid Tumor
- Refractory Rhabdomyosarcoma
- Refractory Soft Tissue Sarcoma
- Refractory WHO Grade 2 Glioma
- Wilms Tumor

## Interventions

- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Radionuclide Imaging
- **DRUG:** Selpercatinib
- **PROCEDURE:** X-Ray Imaging

## Key facts

- **NCT ID:** NCT04320888
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-03
- **Primary completion:** 2024-09-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04320888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04320888, "Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04320888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*